No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
VRTX250117P460000
- 50.15
- +7.04+16.33%
15min DelayClose Jan 14 16:00 ET
51.90High45.60Low
45.60Open43.11Pre Close630 Volume381 Open Interest460.00Strike Price3.10MTurnover97.83%IV0.44%PremiumJan 17, 2025Expiry Date48.34Intrinsic Value100Multiplier2DDays to Expiry1.81Extrinsic Value100Contract SizeAmericanOptions Type-0.9044Delta0.0051Gamma8.28Leverage Ratio-0.9399Theta-0.0246Rho-7.49Eff Leverage0.0588Vega
Intraday
- 5D
- Daily
News
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio With Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
BMO Capital Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $520
Bernstein Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $441
Barclays Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $418
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $418 to $575